Testing a new Lassa fever vaccine
Part of Infections clinical trials.
This trial tests a new vaccine against Lassa fever to see if it is safe and how well it triggers an immune response. It may help protect against this serious infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old
- You are generally healthy (no major medical conditions)
- Your body mass index (BMI) is between 18.5 and 30
- You are not pregnant or breastfeeding, and agree to use contraception if needed
- You have not traveled to a Lassa-endemic country in the past year and are not planning to during the study
- You do not have certain medical conditions like asthma, bleeding disorders, or hearing problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational vaccine to prevent Lassa fever, a serious illness found in parts of West Africa. People in different age groups will get the vaccine or a placebo and be followed to see if it’s safe and helps the immune system respond.
This trial tests different combinations of antiviral drugs (favipiravir, ribavirin, and a steroid called dexamethasone) in adults hospitalized with Lassa fever. The goal is to find the safest and most effective treatment.
This trial tests whether adding dexamethasone, a steroid that reduces inflammation, to standard care can help people with severe Lassa fever. It is for adults who are very sick with confirmed Lassa fever.
This trial tests a new malaria vaccine in healthy adults. It's an early (Phase 1) study, so it's mainly checking safety and how the body responds to the vaccine, not whether it prevents malaria yet.
This study tests a new malaria vaccine to see if it is safe and how the body responds. It involves healthy adults in Burkina Faso who will be monitored closely after vaccination.
This study tests a new malaria vaccine called PfSPZ-LARC2 in healthy adults living in Burkina Faso. If you qualify, the vaccine is given to see if it can protect you from malaria.
Hear when a new Lassa Fever trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.